Odiparcil is a novel, orally bioavailable beta-d-thioxyloside analogue with antithrombotic activity associated with a reduced risk of adverse bleeding events. Its unique mechanism of action is postulated by means of an elevation in circulating endogenous chondroitin sulfate-related glycosaminoglycans (GAGs) levels. References: Myers AL, Upreti VV, Khurana M, Eddington ND. Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparin. J Clin Pharmacol. 2008 Oct;48(10):1158-70. doi: 10.1177/0091270008323751. Epub 2008 Aug 29. PubMed PMID: 18757783. 2: Toomey JR, Abboud MA, Valocik RE, Koster PF, Burns-Kurtis CL, Pillarisetti K, Danoff TM, Erhardt JA. A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4(9):1989-96. PubMed PMID: 16961606.

纯度：≥98%

CAS：137215-12-4